John W. Clader - Concepedia

Author

John W. Clader

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

J. Clader, John Clader, John W Clader, John W. Clader

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Duke University Cornell University LabCorp (United States)

About

John W. Clader is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	54	2.7K
2	Natural Sciences	24	34	2K
3	Health Sciences	4	4	222
4	Engineering	3	3	149
5	Social Sciences	1	1	38

John W. Clader

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Discovery of 1-(4-Fluorophenyl)-(3<i>R</i>)-[3-(4-fluorophenyl)-(3<i>S</i>)- hydroxypropyl]-(4<i>S</i>)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption Stuart B. Rosenblum, Tram Huynh, Adriano Afonso, Journal of Medicinal Chemistry Serum Total CholesterolPharmaceutical SciencePharmacotherapyPharmaceutical ChemistryMolecular Pharmacology	1998	352
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use Alexandra Trkola, Shawn E. Kuhmann, Julie Strizki, Proceedings of the National Academy of Sciences	2002	303
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection<i>in vitro</i>and<i>in vivo</i> Julie Strizki, Serena Xu, Nicole Wagner, Proceedings of the National Academy of Sciences	2001	300
2-Azetidinones as Inhibitors of Cholesterol Absorption Duane A. Burnett, Mary Ann Caplen, Harry R. Davis, Journal of Medicinal Chemistry Molecular PharmacologyMedicinal ChemistryPharmaceutical ChemistryPharmaceutical ScienceBiochemistry	1994	238
Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry Fotini Tsamis, Svetlana Gavrilov, Francis Kajumo, Journal of Virology Ccr5 FunctionImmunologyMolecular BiologySmall-molecule Ccr5Antiviral Drug	2003	204
2-Azetidinone Cholesterol Absorption Inhibitors: Structure−Activity Relationships on the Heterocyclic Nucleus John W. Clader, Duane A. Burnett, Mary Ann Caplen, Journal of Medicinal Chemistry Medicinal ChemistryHeterocyclicPharmacological StudyBiochemistryOxysterol	1996	133
Interaction of small molecule inhibitors of HIV-1 entry with CCR5 Christoph Seibert, Weiwen Ying, Svetlana Gavrilov, Virology MedicineHuman RetrovirusImmunologyAntiviral Drug DevelopmentAntiviral Response	2006	121
Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461 Brian Salisbury, Harry R. Davis, Robert E. Burrier, Atherosclerosis OxysterolBiochemistryMedicineCholesterol AbsorptionSch 48461	1995	108
Design and synthesis of piperidinyl piperidine analogues as potent and selective M2 muscarinic receptor antagonists Yuguang Wang, Samuel Chackalamannil, Zhiyong Hu, Bioorganic & Medicinal Chemistry Letters Piperidinyl Piperidine AnaloguesFunctional SelectivityMedicineMechanism Of ActionPharmacological Agent	2000	96
Discovery of 4-[(<i>Z</i>)-(4-Bromophenyl)- (ethoxyimino)methyl]-1‘-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4‘-methyl-1,4‘- bipiperidine <i>N</i>-Oxide (SCH 351125): An Orally Bioavailable Human CCR5 Antagonist for the Treatment of HIV Infection Anandan Palani, Sherry Shapiro, John W. Clader, Journal of Medicinal Chemistry ImmunologyPharmacotherapyAntiviral DrugPharmaceutical ChemistryMedicinal Chemistry	2001	95

Page 1